Madeline Droney

Madeline Droney

Auto-generated profile, based on publicly available information

Madeline Droney

Department of Pharmacy, The University of Kansas Health System , Kansas City, KS

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2024 in JACCP: Journal of the American College of Clinical Pharmacy
Verified
Journal Article
Closed access
SHSarah M. Hayes
Sarah M. Hayes
DMDonald C. Moore
Donald C. Moore
MDMadeline Droney
Madeline Droney
SJSteven T. Johnson
Steven T. Johnson
MRMegan A. Rech
Megan A. Rech
TSThomas Szymanski
Thomas Szymanski

28 January 2025 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
MDMadeline Droney
Madeline Droney
ERErica Reed
Erica Reed
SSSajed Sarwar
Sajed Sarwar
KCKelci Coe
Kelci Coe
NTNikki Tran
Nikki Tran
Objectives: Candida glabrata is the second most common species responsible for invasive candidiasis, including candidaemia. Echinocandins are typically the first-line therapy for C. glabrata candidaemia, with the option to transition to oral fluconazole. Studies are needed to evaluate clinical outcomes in patients initially treated with echinocandins then transitioned to fluconazole. Methods: This was a retrospective, single-centre cohort study of patients with C. glabrata candidaemia from November 2011 to August 2023. Inpatients aged 18–89 years who received an echinocandin within 24 h of the initial positive blood culture were included. Patients were excluded if they received antifungal treatment less than 48 h, combination therapy, or fluconazole as initial therapy. The primary composite outcome was 30-day clinical failure. Results: A total of 186 patients were included (n = 153 echinocandin only; n = 33 fluconazole step-down). The most common source of candidaemia was line-associated in both groups with the majority having source control (43% echinocandin versus 58% fluconazole; P = 0.32). Compared to fluconazole, patients in the echinocandin group had a higher rate of concomitant bacteraemia (45% versus 24%; P = 0.03) and endovascular complications (11% versus 0%; P = 0.05). There was no significant difference in treatment duration between echinocandin and fluconazole (16 versus 19 days; P = 0.46), incidence of persistent candidaemia (22% versus 24%; P = 0.7), or 30-day clinical failure (15% versus 9%; P = 0.58). Conclusions: Fluconazole appears to be a safe and reasonable step-down therapy in the management of C. glabrata candidaemia.